Ensoma Overview
- Year Founded
-
2019
- Status
-
Private
- Employees
-
67
- Latest Deal Type
-
2ndary - Private
- Investors
-
18
Ensoma General Information
Description
Developer of an in vivo hematopoietic stem cell engineering platform designed to advance one-time genomic medicines for genetic diseases, immune disorders, and cancer. The company focuses on engineered vectors that permit to delivery of gene modification technologies directly to stem cells or the various cell types that arise from these cells, such as T cells, B cells, and myeloid cells, without the need for stem cell collection or prior conditioning, which can be toxic to patients, enabling health professionals to have access to genomic medicines that can be delivered in a single injection.
Contact Information
Website
www.ensoma.comCorporate Office
- 451 D Street
- Suite 600
- Boston, MA 02210
- United States
Corporate Office
- 451 D Street
- Suite 600
- Boston, MA 02210
- United States
Ensoma Timeline
Ensoma Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 4. Secondary Transaction - Private | Completed | Clinical Trials - Phase 1 | ||||
| 3. Later Stage VC (Series B1) | 22-Sep-2025 | Completed | Clinical Trials - Phase 1 | |||
| 2. Early Stage VC (Series B) | 16-May-2023 | $135M | $205M | Completed | Clinical Trials - General | |
| 1. Early Stage VC (Series A) | 19-Feb-2021 | $70M | $70M | Completed | Pre-Clinical Trials |
Ensoma Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series B | ||||||||
| Series A-1 | ||||||||
| Series A | 35,688,784 | $0.000100 | $1.68 | $1.68 | 1x | $1.52 | 19.01% |
VC Exit Predictor
See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.
Opportunity Score
Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.
Exit Type
Evaluates the likelihood of a successful exit for investors, and the most likely exit type.
Ensoma Comparisons
Industry
Financing
Details
Ensoma Competitors (43)
One of Ensoma’s 43 competitors is Obsidian Therapeutics, a Formerly VC-backed company based in Cambridge, MA.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Obsidian Therapeutics | Formerly VC-backed | Cambridge, MA | ||||
| Kite Pharma | Formerly VC-backed | Santa Monica, CA | ||||
| Prevail Therapeutics | Formerly VC-backed | New York, NY | ||||
| Allogene Therapeutics | Formerly VC-backed | South San Francisco, CA | ||||
| Adaptimmune Therapeutics | Formerly VC-backed | Abingdon, United Kingdom |
Ensoma Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
Ensoma Patents
Ensoma Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2026193412-A1 | Methods of adenoviral gene therapy | Pending | 14-Mar-2025 | ||
| WO-2026143185-A1 | Engineered rna-guided dna-binding polypeptides | Inactive | 23-Dec-2024 | ||
| WO-2026073258-A2 | Adenoviral gene therapy vectors and methods of use thereof | Pending | 30-Sep-2024 | ||
| WO-2026073258-A3 | Adenoviral gene therapy vectors and methods of use thereof | Pending | 30-Sep-2024 | ||
| WO-2026073244-A1 | Constructs for multi-lineage expression of therapeutic agents | Pending | 30-Sep-2024 | A61K40/11 |
Ensoma Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
Ensoma Investors (18)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| AJU IB Investment | Venture Capital | Minority | ||
| Hanwha Impact | Impact Investing | Minority | ||
| Delos Capital Partners | Venture Capital | Minority | ||
| Gates Foundation | Not-For-Profit Venture Capital | Minority | ||
| Gilead | Corporation | Minority |
Ensoma Acquisitions (1)
Ensoma’s most recent deal was a Merger/Acquisition with Twelve bio. The deal was made on 05-Jan-2023.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| Twelve bio | 05-Jan-2023 | Merger/Acquisition | Other Healthcare Technology Systems |
Ensoma FAQs
-
When was Ensoma founded?
Ensoma was founded in 2019.
-
Where is Ensoma headquartered?
Ensoma is headquartered in Boston, MA.
-
What is the size of Ensoma?
Ensoma has 67 total employees.
-
What industry is Ensoma in?
Ensoma’s primary industry is Drug Discovery.
-
Is Ensoma a private or public company?
Ensoma is a Private company.
-
What is Ensoma’s current revenue?
The current revenue for Ensoma is .
-
How much funding has Ensoma raised over time?
Ensoma has raised $258M.
-
Who are Ensoma’s investors?
AJU IB Investment, Hanwha Impact, Delos Capital Partners, Gates Foundation, and Gilead are 5 of 18 investors who have invested in Ensoma.
-
Who are Ensoma’s competitors?
Obsidian Therapeutics, Kite Pharma, Prevail Therapeutics, Allogene Therapeutics, and Adaptimmune Therapeutics are some of the 43 competitors of Ensoma.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
